NasdaqGS:ANABBiotechs
Does AnaptysBio’s (ANAB) Legal Win on Jemperli Royalties Reshape Its Partnership Power Balance?
In April 2026, AnaptysBio announced that the Delaware Chancery Court dismissed Tesaro’s anticipatory breach of contract claim, rejecting Tesaro’s bid to cut Jemperli royalties and affirming that AnaptysBio had not repudiated their Collaboration and Exclusive License Agreement.
The ruling removes a key legal challenge to AnaptysBio’s royalty stream while clearing the way for a July 2026 trial on AnaptysBio’s allegations that Tesaro and GSK materially breached the collaboration, including...